Previous close | 43.35 |
Open | 44.93 |
Bid | 44.89 x 100 |
Ask | 45.21 x 200 |
Day's range | 42.12 - 45.13 |
52-week range | 18.00 - 53.92 |
Volume | |
Avg. volume | 1,169,915 |
Market cap | 3.342B |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.15 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 66.78 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc